NEW YORK (GenomeWeb News) – Compugen today said that Teva Pharmaceutical industries has exercised its option to utilize in its research activities a combination of biomarkers discovered by the firm for early detection of drug-induced nephrotoxicity.

The biomarkers were discovered under a collaboration between the two firms in 2007. Compugen used its computational tools, discovery engines, and nucleic acid testing platforms, as well as data from Teva, in a preclinical study.

To read the full story....

Register for Free.

...and receive Daily News bulletins.

Already have a GenomeWeb or 360Dx account?
Login Now.

An artificial intelligence-based analysis suggests a third group of ancient hominins likely interbred with human ancestors, according to Popular Mechanics.

In Science this week: reduction in bee phylogenetic diversity, and more.

The New York Times Magazine looks into paleogenomics and how it is revising what's know about human history, but also possibly ignoring lessons learned by archaeologists.

The Economist reports on Synthorx's efforts to use expanded DNA bases they generated to develop a new cancer drug.

Sponsored by
L7 Informatics

This webinar will provide a first-hand look at how Gradalis, a clinical-stage immunotherapy developer, is using an information management solution from L7 to streamline its research, clinical, and manufacturing operations.